ABVC vs. GRTX, IMNN, PPBT, MNPR, RDHL, ELAB, ERNA, ATHE, AEZS, and MIRA
Should you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Galera Therapeutics (GRTX), Imunon (IMNN), Purple Biotech (PPBT), Monopar Therapeutics (MNPR), RedHill Biopharma (RDHL), Elevai Labs (ELAB), Eterna Therapeutics (ERNA), Alterity Therapeutics (ATHE), Aeterna Zentaris (AEZS), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Galera Therapeutics (NASDAQ:GRTX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.
Galera Therapeutics received 50 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
In the previous week, ABVC BioPharma had 2 more articles in the media than Galera Therapeutics. MarketBeat recorded 3 mentions for ABVC BioPharma and 1 mentions for Galera Therapeutics. Galera Therapeutics' average media sentiment score of 0.76 beat ABVC BioPharma's score of -1.00 indicating that ABVC BioPharma is being referred to more favorably in the news media.
50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 6.9% of Galera Therapeutics shares are held by insiders. Comparatively, 11.9% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Galera Therapeutics has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Galera Therapeutics has a net margin of 0.00% compared to Galera Therapeutics' net margin of -6,919.08%. ABVC BioPharma's return on equity of 0.00% beat Galera Therapeutics' return on equity.
ABVC BioPharma has higher revenue and earnings than Galera Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Galera Therapeutics beats ABVC BioPharma on 7 of the 13 factors compared between the two stocks.
Get ABVC BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABVC BioPharma Competitors List
Related Companies and Tools
